Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre‐Administration in a Randomized, Double‐Blind, Cross‐Over Phase I Trial
Open Access
- 28 February 2025
- journal article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (6) , 1784-1792
Abstract
Psychedelics, such as psilocybin and lysergic acid diethylamide (LSD), are being investigated for the treatment of depressive and anxiety disorders, for which concomitant treatment with selective serotonin reuptake inhibitors (SSRIs) is prevalent. The present study investigated the acute response to single doses of LSD (100 μg) after daily administration of paroxetine (10 mg for 7 days, followed by 20 mg for 35 days) or placebo (42 days) using a randomized, double‐blind, cross‐over design in 23 healthy participants. Paroxetine did not alter pleasant subjective effects of LSD but significantly reduced “bad drug effect,” “anxiety,” and “nausea.” No differences in autonomic effects or QTc interval after LSD administration were found between both conditions. The strong cytochrome P450 2D6 (CYP2D6) inhibitor paroxetine led to higher maximal concentrations and total exposures of LSD (geometric mean ratios of 1.4 and 1.5, respectively) indicating relevant involvement of CYP2D6 in its metabolism. The extent of this inhibition was nominally highest in genetic CYP2D6 normal metabolizers and lowest in poor metabolizers. The present findings suggest that add‐on treatment with LSD to an SSRI is well‐tolerated. The pharmacokinetic and pharmacodynamic interactions indicate that no dose adjustment of LSD seems necessary in the presence of an SSRI that inhibits CYP2D6. For SSRIs that do not relevantly inhibit CYP2D6, a dose increase of LSD might be appropriate, but due to lacking data and potential other pharmacokinetic interactions with these compounds, no definitive dose recommendation can be made.Keywords
This publication has 47 references indexed in Scilit:
- Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double‐Blind, Placebo‐Controlled, Crossover Study in Healthy SubjectsClinical Pharmacology & Therapeutics, 2021
- Safety pharmacology of acute LSD administration in healthy subjectsPsychopharmacology, 2021
- Serotonin toxicity of serotonergic psychedelicsPsychopharmacology, 2021
- Development and validation of an LC‐MS/MS method to quantify lysergic acid diethylamide (LSD), iso‐LSD, 2‐oxo‐3‐hydroxy‐LSD, and nor‐LSD and identify novel metabolites in plasma samples in a controlled clinical trialJournal of Clinical Laboratory Analysis, 2017
- Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effectsPsychopharmacology, 2011
- Profiling of behavioral changes and hippocampal gene expression in mice chronically treated with the SSRI paroxetinePsychopharmacology, 2008
- Early Onset of Selective Serotonin Reuptake Inhibitor Antidepressant ActionArchives of General Psychiatry, 2006
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significancePsychopharmacology, 2006
- Effects of Fluvoxamine Treatment on the in Vivo Binding of [F-18]FESP in Drug Naive Depressed Patients: A Pet StudyNeuroImage, 2000
- Chronic Administration of Serotonergic Antidepressants Attenuates the Subjective Effects of LSD in HumansNeuropsychopharmacology, 1996